Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (NCT05280470)

🧪 Interventions in This Study

• Ifinatamab Deruxtecan (I-DXd) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (58 Sites)

Showing the first 25 of 58 sites.

• Highlands Oncology Group — Springdale, Arkansas
• The Cancer Specialists, Llc — Jacksonville, Florida
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
• University of Chicago Medical Center — Chicago, Illinois
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
• Dana-Faeber Cancer Institute — Boston, Massachusetts
• Henry Ford Hospital — Detroit, Michigan
• Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan
• Washington University School of Medicine — St Louis, Missouri
• Hackensack Meridian Health-Southern Ocean Medical Center — Manahawkin, New Jersey
• Memorial Sloan-Kettering Cancer Center (Mskcc) - New York — New York, New York
• Montefiore Medical Center Prime — The Bronx, New York
• Duke University Health System — Durham, North Carolina
• Sarah Cannon (Tennessee Oncology - Nashville) — Nashville, Tennessee
• Millennium Physicians Association, Llp — Houston, Texas
• University of Washington Medical Center — Seattle, Washington
• Jilin Cancer Hospital — Changchun,
• Hunan Cancer Hospital — Changsha,
• West China Hospital, Sichuan University — Chengdu,
• Guangdong Provincial People'S Hospital — Guangdong,
• Zhejiang Cancer Hospital — Hangzhou,
• Linyi Cancer Hospital — Linyi,
• Fudan University Shanghai Cancer Center — Shanghai,
• Union Hospital of Tongji Medical College Huazhong University of Science and Technology — Wuhan,
• Centre Hospitalier Intercommunal de Créteil — Créteil,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Extensive-stage Small-cell Lung Cancer

• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Mobile, Alabama
• Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy — Anchorage, Alaska
• MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer — Washington D.C., District of Columbia
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC — Los Angeles, California
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer — Tucson, Arizona

Explore by condition: All Extensive-stage Small-cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.